A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of previously treated Locally Advanced and unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

  • Briggs, Peter (Primary Chief Investigator (PCI))

Project: Research

Project Details

Effective start/end date5/05/204/05/25


  • clinical trial
  • phase 3 study
  • treatment safety
  • treatment efficacy
  • KRAS G12C